Top

Cardiovascular Diabetology

Published in:

Open Access 01-12-2023 | Arterial Diseases | Research

Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease

Authors: Mitsuyoshi Takahara, Yoshimitsu Soga, Masahiko Fujihara, Osamu Iida, Daizo Kawasaki

Published in: Cardiovascular Diabetology | Issue 1/2023

Abstract

Background

This study aimed to reveal the prevalence of sodium-glucose co-transporter 2 (SGLT2) inhibitor treatment and its association with restenosis risk in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease.

Methods

We used the database of a multicenter prospective study registering patients with symptomatic peripheral artery disease undergoing femoropopliteal drug-coated balloon treatment in Japan. The current analysis included 1058 patients with diabetes mellitus free from end-stage renal disease. The association of clinical characteristics with SGLT2 inhibitor use was investigated using the logistic regression model. The propensity score matching was adopted to compare the primary patency, i.e., freedom from restenosis, after endovascular therapy between patients treated with and without a SGLT2 inhibitor.

Results

The proportion of SGLT2 inhibitor treatment at revascularization was 14.8% (95% confidence interval, 12.8–17.1%). Younger age, increased body mass index, and increased hemoglobin A1c levels were independently associated with SGLT2 inhibitor use (all P < 0.05). The proportion of SGLT2 inhibitor reached 38.2% (95% confidence interval, 25.4–52.3%) in patients with the three associated factors. The propensity score-matching analysis demonstrated that primary patency was not different between patients treated with a SGLT2 inhibitor and those without it (72.0% [95% confidence interval, 64.1–80.9%] versus 67.8% [62.7–73.3%] at 2 years; P = 0.45).

Conclusions

SGLT2 inhibitors were not rarely used in patients with diabetes mellitus who underwent femoropopliteal endovascular therapy using a drug coated balloon for symptomatic peripheral artery disease in real-world settings. SGLT2 inhibitor treatment was not associated with an increased risk of restenosis.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.PubMedCrossRef

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.PubMedCrossRef

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.PubMedCrossRef

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with Cardiovascular and kidney outcomes in patients with type 2 diabetes: a Meta-analysis. JAMA Cardiol. 2021;6:148–58.PubMedCrossRef

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.PubMedCrossRef

Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular Outcomes and Risks after initiation of a Sodium glucose cotransporter 2 inhibitor: results from the EASEL Population-Based Cohort Study (evidence for Cardiovascular Outcomes with Sodium glucose cotransporter 2 inhibitors in the Real World). Circulation. 2018;137:1450–9.PubMedPubMedCentralCrossRef

Yuan Z, DeFalco FJ, Ryan PB, Schuemie MJ, Stang PE, Berlin JA, et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes Metab. 2018;20:582–9.PubMedCrossRef

Adimadhyam S, Lee TA, Calip GS, Smith Marsh DE, Layden BT, Schumock GT. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: a propensity-matched cohort study. Diabetes Obes Metab. 2018;20:2792–9.PubMedCrossRef

Paul SK, Bhatt DL, Montvida O. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. Eur Heart J. 2021;42:1728–38.PubMedCrossRef

10.

Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between Sodium-Glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med. 2018;178:1190–8.PubMedPubMedCentralCrossRef

11.

Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018;20:2585–97.PubMedPubMedCentralCrossRef

12.

Ueda P, Svanstrom H, Melbye M, Eliasson B, Svensson AM, Franzen S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365.PubMedPubMedCentralCrossRef

13.

Vlachopoulos C, Terentes-Printzios D, Tsioufis K. Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly. Eur Heart J. 2021;42:1739–41.PubMedCrossRef

14.

Potier L, Mohammedi K, Velho G, Roussel R. SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis. Cardiovasc Diabetol. 2021;20:107.PubMedPubMedCentralCrossRef

15.

Lytvyn Y, Bjornstad P, Katz A, Singh SK, Godoy LC, Chung LT, et al. SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. Diabetes Metab. 2020;46:203–9.PubMedCrossRef

16.

Potier L, Roussel R, Marre M, Bjornstad P, Cherney DZ, El Boustany R, et al. Plasma copeptin and risk of Lower-Extremity Amputation in Type 1 and type 2 diabetes. Diabetes Care. 2019;42:2290–7.PubMedPubMedCentralCrossRef

17.

McClure JM, Rossi NF, Chen H, O’Leary DS, Scislo TJ. Vasopressin is a major vasoconstrictor involved in hindlimb vascular responses to stimulation of adenosine A(1) receptors in the nucleus of the solitary tract. Am J Physiol Heart Circ Physiol. 2009;297:H1661–72.PubMedPubMedCentralCrossRef

18.

Liu ZW, Gu H, Zhang BF, Zhao YH, Zhao JJ, Zhao YL, et al. Rapidly increased vasopressin promotes acute platelet aggregation and early brain injury after experimental subarachnoid hemorrhage in a rat model. Brain Res. 2016;1639:108–19.PubMedCrossRef

19.

Schill F, Persson M, Engstrom G, Melander O, Enhorning S. Copeptin as a marker of atherosclerosis and arteriosclerosis. Atherosclerosis. 2021;338:64–8.PubMedPubMedCentralCrossRef

20.

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(Suppl 1):1–75.CrossRef

21.

Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial Diseases, in collaboration with the european society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the european Stroke Organization (ESO)the Task Force for the diagnosis and treatment of peripheral arterial Diseases of the European Society of Cardiology (ESC) and of the european society for vascular surgery (ESVS). Eur Heart J. 2018;39:763–816.PubMedCrossRef

22.

Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–e79.PubMed

23.

Takahara M, Kaneto H, Iida O, Gorogawa S, Ikeda M. High prevalence of glucose intolerance in japanese patients with peripheral arterial disease. Diabetes Res Clin Pract. 2011;91:e24–5.PubMedCrossRef

24.

Takahara M, Iida O, Kohsaka S, Soga Y, Fujihara M, Shinke T, et al. Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases. Cardiovasc Diabetol. 2019;18:155.PubMedPubMedCentralCrossRef

25.

Soga Y, Takahara M, Iida O, Tomoi Y, Kawasaki D, Tanaka A, et al. Vessel Patency and Associated factors of drug-coated balloon for Femoropopliteal Lesion. J Am Heart Assoc. 2023;12:e025677.PubMedCrossRef

26.

Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese clinical practice Guideline for Diabetes 2019. Diabetol Int. 2020;11:165–223.PubMedPubMedCentralCrossRef

27.

Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.PubMedCrossRef

28.

Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018;25:846–984.PubMedPubMedCentralCrossRef

29.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRef

30.

Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the japanese general population. Clin Exp Nephrol. 2009;13:621–30.PubMedCrossRef

31.

Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69:3S–125Se40.PubMedPubMedCentralCrossRef

32.

Iida O, Takahara M, Soga Y, Fujihara M, Kawasaki D, Hirano K et al. Vessel diameter evaluated by Intravascular Ultrasound Versus Angiography. J Endovasc Ther. https://doi.org/10.1177/15266028211047946:15266028211047946.

33.

Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83:E212–20.PubMedCrossRef

34.

Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65:931–41.PubMedPubMedCentralCrossRef

35.

The European Medicines Agency. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. Volume 28. Accessed; 2022. https://www.ema.europa.eu/en/news/sglt2-inhibitors-information-potential-risk-toe-amputation-be-included-prescribing-information.

36.

The US Food and Drug Administration. FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet. Volume 28. Accessed; 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine.

37.

Tanji Y, Sawada S, Watanabe T, Mita T, Kobayashi Y, Murakami T, et al. Impact of COVID-19 pandemic on glycemic control among outpatients with type 2 diabetes in Japan: a hospital-based survey from a country without lockdown. Diabetes Res Clin Pract. 2021;176:108840.PubMedPubMedCentralCrossRef

38.

Yagi N, Komiya I, Arai K, Oishi M, Fukumoto Y, Shirabe S, et al. Current status of oral antidiabetic drug prescribing patterns based on the body mass index for japanese type 2 diabetes mellitus patients and yearly changes in diabetologists’ prescribing patterns from 2002 to 2019 (JDDM61). J Diabetes Investig. 2022;13:65–73.PubMedCrossRef

39.

Bellary S, Barnett AH. SGLT2 inhibitors in older adults: overcoming the age barrier. Lancet Healthy Longev. 2023;4:e127–e8.PubMedCrossRef

40.

Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the american Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetologia. 2018;61:2461–98.PubMedCrossRef

41.

Bouchi R, Sugiyama T, Goto A, Imai K, Ihana-Sugiyama N, Ohsugi M, et al. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. J Diabetes Investig. 2022;13:280–91.PubMedCrossRef

42.

Wannamethee SG, Welsh P, Lennon L, Papacosta O, Whincup PH, Sattar N. Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: the british Regional Heart Study. Diabetologia. 2016;59:1904–12.PubMedPubMedCentralCrossRef

43.

Bar-Shalom D, Poulsen MK, Rasmussen LM, Diederichsen AC, Sand NP, Henriksen JE, et al. Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patients. Diab Vasc Dis Res. 2014;11:448–50.PubMedCrossRef

44.

Fatemi S, Acosta S, Gottsater A, Melander O, Engstrom G, Dakhel A, et al. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD. Biomarkers. 2019;24:615–21.PubMedCrossRef

45.

Ozkaramanli Gur D, Gur O, Guzel S, Akyuz A, Gurkan S, Alpsoy S, et al. Inflammatory Mediators across the Spectrum of Ankle-Brachial Index. J Atheroscler Thromb. 2019;26:351–61.PubMedCrossRef

46.

Chiodera P, Volpi R, Capretti L, Speroni G, Marcato A, Rossi G, et al. Hypoglycemia-induced arginine vasopressin and oxytocin release is mediated by glucoreceptors located inside the blood-brain barrier. Neuroendocrinology. 1992;55:655–9.PubMedCrossRef

47.

Keppens S, de Wulf H. The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochim Biophys Acta. 1979;588:63–9.PubMedCrossRef

48.

Bankir L, Bardoux P, Ahloulay M. Vasopressin and diabetes mellitus. Nephron. 2001;87:8–18.PubMedCrossRef

49.

Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000;106:107–16.PubMedPubMedCentralCrossRef

50.

Juul KV, Bichet DG, Nielsen S, Norgaard JP. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol. 2014;306:F931–40.PubMedCrossRef

51.

Kosiborod MN, Vaduganathan M. SGLT-2 inhibitors in Heart failure: volume or value? J Am Coll Cardiol. 2021;77:1393–6.PubMedCrossRef

52.

Horie K, Tanaka A, Taguri M, Inoue N. Impact of baseline and Postprocedural Intravascular Ultrasound Findings on 1-Year primary patency after drug-coated balloon treatment of Femoropopliteal Lesions. J Endovasc Ther. 2022;29:66–75.PubMedCrossRef

53.

Yu X, Zhang X, Lai Z, Shao J, Zeng R, Ye W, et al. One-year outcomes of drug-coated balloon treatment for long femoropopliteal lesions: a multicentre cohort and real-world study. BMC Cardiovasc Disord. 2021;21:326.PubMedPubMedCentralCrossRef

54.

Tepe G, Zeller T, Moscovic M, Corpataux JM, Christensen JK, Keirse K, et al. Paclitaxel-Coated Balloon Angioplasty for the treatment of Infrainguinal arteries: 24-Month Outcomes in the full cohort of BIOLUX P-III Global Registry. Cardiovasc Intervent Radiol. 2021;44:207–17.PubMedCrossRef

55.

Horie K, Takahara M, Nakama T, Tanaka A, Tobita K, Hayakawa N, et al. Impact of postoperative Lumen Gain on the reduction of Restenosis Risk after Endovascular Treatment using drug-coated balloon for Femoropopliteal Lesions assessed by Intravascular Ultrasound. J Atheroscler Thromb. 2022. https://doi.org/10.5551/jat.63886.CrossRefPubMedPubMedCentral

56.

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.PubMedPubMedCentralCrossRef

57.

Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;392:1541–51.PubMedCrossRef

58.

Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015;373:145–53.PubMedCrossRef

Title: Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease
Authors: Mitsuyoshi Takahara
Yoshimitsu Soga
Masahiko Fujihara
Osamu Iida
Daizo Kawasaki
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Arterial Diseases
Diabetes
Published in: Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-023-01992-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease

Rapid kidney function decline and increased risk of heart failure in patients with type 2 diabetes: findings from the ACCORD cohort

The triglyceride-glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001–2018

L-Arginine in diabetes: clinical and preclinical evidence

Association between triglyceride-glucose index and all-cause mortality in critically ill patients with ischemic stroke: analysis of the MIMIC-IV database

Epicardial adipose tissue density is a better predictor of cardiometabolic risk in HFpEF patients: a prospective cohort study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials